Primary resistance to CD19-CAR T cell therapy is observed in roughly 50% of DLBCL, around 10% of MCL, and 5–15% of FL cases, while secondary resistance happens in around 40–50% of DLBCL, 40% of MCL, and 30% of FL [11]. Here, CD19 is linked to diffuse large B-cell lymphoma.